CTMX Earnings & Financial Statements
CytomX Therapeutics, Inc.
$2.38
+$0.15(+6.50%)
45
Overall
45
Value
45
Tech
47
Quality
Market Cap
$485.92M
Volume
957.00K
52W Range
$2.43 - $8.21
Target Price
$12.25
CTMX earnings and financial statements: CytomX Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CTMX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $76.20M | $138.10M | $101.21M | $53.16M | $37.31M |
| Operating income | -$22.36M | $25.00M | -$6.48M | -$101.33M | -$116.04M |
| EBITDA | -$16.98M | $32.24M | $5.50M | -$98.89M | -$113.34M |
| Net income | -$17.37M | $31.87M | -$569.0K | -$99.32M | -$115.87M |
| EPS (diluted) | $-0.15 | $0.38 | $-0.01 | $-1.51 | $-1.30 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $151.57M | $120.53M | $201.79M | $260.89M | $339.41M |
| Total liabilities | $52.56M | $120.99M | $249.24M | $346.64M | $339.87M |
| Shareholders’ equity | $99.01M | -$456.0K | -$47.45M | -$85.75M | -$459.0K |
| Cash and equivalents | $12.67M | $38.05M | $17.17M | $193.65M | $205.53M |
| Long-term debt | - | $4.24M | $9.38M | $13.97M | $18.06M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$75.59M | -$86.23M | -$56.03M | -$110.79M | -$119.03M |
| Capital expenditure | -$220.0K | -$310.0K | -$840.0K | -$1.74M | -$1.61M |
| Free cash flow | -$75.81M | -$86.54M | -$56.88M | -$112.53M | -$120.64M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CTMX | $2.38 | +6.5% | 957.00K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get CytomX Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW